Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)

NCT03394482 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT03394482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
January 3, 2018
Completion date
October 5, 2018
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy